Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 59.01M P/E - EPS this Y 23.80% Ern Qtrly Grth -
Income -54.15M Forward P/E -1.38 EPS next Y 27.10% 50D Avg Chg -5.00%
Sales 3.8M PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 5.22 EPS next 5Y - 52W High Chg -61.00%
Recommedations 1.80 Quick Ratio 1.65 Shares Outstanding 49.34M 52W Low Chg 28.00%
Insider Own 64.95% ROA -72.73% Shares Float 18.93M Beta 1.46
Inst Own 3.70% ROE -300.52% Shares Shorted/Prior 363.25K/577.17K Price 1.41
Gross Margin -67.40% Profit Margin - Avg. Volume 54,000 Target Price 3.71
Oper. Margin -1,146.72% Earnings Date Nov 11 Volume 10,739 Change -2.76%
About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc. News
07:23 AM Lucid Inks New Partnership With VITALExam: Stock to Gain?
12/23/24 Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
12/19/24 Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
12/11/24 Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
12/03/24 Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
11/20/24 Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
11/18/24 Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
11/15/24 Q3 2024 PAVmed Inc Earnings Call
11/15/24 PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring
11/14/24 PAVmed Provides Business Update and Third Quarter 2024 Financial Results
11/14/24 Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ...
11/13/24 Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
11/07/24 Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
11/05/24 Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers
10/31/24 PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
10/30/24 Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024
10/15/24 Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
10/15/24 Castle Biosciences price target raised to $40 from $35 at BTIG
10/09/24 Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
10/08/24 Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
LUCD Chatroom

User Image PAVM_Millionaire Posted - 1 day ago

$PAVM $LUCD Merry Christmas to all! (Well, everyone except that Grinch @LPlates McCarthy) I hope your esophaguses enjoy some great food tomorrow. The best present I could ask for is for Mr Aklog and Dennis to deliver some good news and shareholder value 🎁 Some of us may feel like George Bailey waiting for that ending in a Wonderful Life so hopefully that comes in 2025 🤞 In the end it doesn’t matter if it goes bankrupt or how foolish one might feel for getting so deep here, because there’s much more to life. Enjoy time with your family and trust in Jesus for your salvation and how to live your life. It’s amazing how much peace that brings! Best of luck to all here next year and beyond 😃

User Image Carter113 Posted - 2 days ago

$LUCD $PAVM https://jewishlink.news/esophageal-cancer-can-be-caught-early/

User Image oaksapollo Posted - 2 days ago

$LUCD @okay22 you're looking at the wrong number. Look at the prevalence of GERD, obesity, white males, etc, these are the numbers that will drive Esoguard revenue. Also, if you want to focus on esophageal cancer, look at Asia. Lucid is barely scratching the surface with the US opportunity.

User Image okay22 Posted - 2 days ago

$LUCD the only problem with this situation is that eso cancer isn't that common. It's wild. Cologuard is successful because it is 10% of worldwide cancers. Eso cancer is 1%. But the kicker is, 1% of worldwide cancers is still a gd lot of freaking people.

User Image LPlates Posted - 3 days ago

@Carter113 @xx007xx So how many shares of $LUCD are being used by Stocktwit, Yahoo SeekingAlpha, Schwab etc to calculate the market cap? Is that number the same as Lishan, the CEO of both $LUCD and $PAVM said we're outstanding at the latest Conference call? Could there be a 70 MILLION share difference because they are outstanding but have not been ISSUED yet? These are just simple FACTS. The fact that you have got them wrong means you are an idiot or that you mislead. Which is it? You will go all quiet now like you have done EVERY time you have been called out.

User Image Carter113 Posted - 3 days ago

$LUCD $PAVM LPlates The almighty Dave McCarthy, the guy who posts under multiple aliases (that point alone makes you SHADY as shit, I mean WTF you just wake up one morning and think oh I will create another profile so they don’t know who I am??? Then your so dumb you start posting under the wrong one, this is the guy who lost his ass himself investing in this company and now just trolls the the message boards spewing the next phase of his BS story since all the other versions have yet to play out! 1) Arynton is out of LUCD now, that’s story is over! 2) Arynton surrendered all of their collateral over the assets of PAVM, and are now capped at a 30% max return on their 25m debt that will be converted to a preferred, that story is now over! 3) Oh and Dave let m do some simple math for you, the 31.M shares of LUCD that PAVM owns times the current price of .775 is not 8M as you tried to claim today you moron!!! Must I go on and on……you 🤡 Nope I have better things to do! No one cares Dave!🖕

User Image supDawg Posted - 3 days ago

$LUCD

User Image LPlates Posted - 3 days ago

@xx007xx but I've been right and you have been wrong. That's just a fact. Lishan and Dennis have kept the doors open by any way possible to keep collecting their $60k a month EACH. But I'd $LUCD or $PAVM in a better position today than they were a year ago? So specific points on what positive progress has been made in the last 12 months. And if you say CMS submissions please detail what has been the cost to retail investors and confirm that you think that is a positive. I will then show you and everyone that you are an idiot. So 2 choices. 1. Shut up. 2. Be shown to be an idiot. If you don't put up I will be disappointed but I can't see how you can. Tik tok. Tik tok.

User Image xx007xx Posted - 3 days ago

$LUCD $PAVM this account is constantly trying to bash everything about this company. Funny thing, it’s been saying that the doors should be closed now for a year. Now, it’s saying that it believe CMS coverage will be granted in Q2 of 25. Boy, you’ve been wrong so much that everyone tunes out the nonsensical posts that are done each day…

User Image LPlates Posted - 3 days ago

$PAVM $LUCD There are a few days available for tax loss selling. And then there is the promise of 2025. But ...... If you believe the following then it should help you create a winning strategy. EsoGuard will get CMS coverage probably 2Q 25. Then it will need a very large offering in relation to it's market cap. Wall Street knows this so any run up will be day traders and it will be brief. There will be no institutional money because ... 1. They can get a worthwhile size if they believe the EsoGuard story (BIG if imo!) 2. Probability there will be warrants attached which they LOVE. The more I think of this the more I think it's a non trivial possibility. If Elon / DOGE want to take 2 TRILLION out of entitlements the first thing I would do is make sure there were no new additions to the entitlement pot. I'd via executive order on day 1 say that any new program that could cost $1b or more annually must get sign off from DOGE. That would be CATASTROPHIC for PAVM / LUCD

User Image oaksapollo Posted - 3 days ago

$LUCD @pavie99 claims blood tests will have "good detection" for esophageal cancer in 2-3 years and that the tech just "isn't public yet." He's "in the bio space" so we're just supposed to trust him. I'm calling BS for several reasons: 1) SSBE means characteristics of the intestine are present in the esophagus. Most of the time (88%) there is no dysplasia so how would you measure that systemically via the blood? How would you distinguish intestine in the esophagus vs intestine in the intestine? 2) ECAN just had a whole seminar on blood tests for cancer screening. It was quite clear no one is close to catching esophageal cancer via the blood (20% sensitivity). 3) The key feature of Esoguard is that has good sensitivity for SSBE. Even EXAS with all it's billions cannot do this. If anyone has actual evidence supporting a blood test for SSBE I'd love to see it, but am quite confident @pavie99 is full of #&%@.

User Image traderjoe2018 Posted - 3 days ago

$PAVM extension granted for $LUCD. Can we get it for PAVM too please?

User Image UncleJuniorrr Posted - 3 days ago

$LUCD the first part of the email said granted and I thought it was going be coverage news

User Image supDawg Posted - 3 days ago

$LUCD awful news.

User Image Scanners_Free Posted - 3 days ago

$LUCD NNNNNEEEEEEEWWWSSS

User Image supDawg Posted - 3 days ago

$LUCD $PAVM if the market truly believed they would get LCD coverage, the stock should be trending up, not down even after immense selling by a vulture fund. Something really stinks here. It's not looking good as I've stated multiple times after yet another convertible note has been issued. A sane mgmt team would sell off the assets by now, but they need to keep the grift going. Michael Glennon is also the dumbest person on the planet. He has purchased stock 2x now with his own money (as an insider!) and is down bad on both. My goodness.

User Image RetiredMD Posted - 5 days ago

$LUCD 2 million upper endoscopies a year performed in the United States for GERD alone ($1938 x 2mm=$3.876 Billion in revenue)

User Image TD_ Posted - 6 days ago

$LUCD $PAVM $125m Mixed Shelf filed... On December 19, 2024, Lucid Diagnostics received a letter from the Nasdaq Listing Qualifications department notifying Lucid Diagnostics that it would be afforded an additional 180 calendar days (or until June 16, 2025) to regain compliance with Nasdaq’s minimum bid price requirement https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318801551&type=HTML&symbol=PAVM&cdn=a30aa9aa41a08ee0370511a790609d41&companyName=PAVmed+Inc.&formType=S-3&dateFiled=2024-12-20#mj_005

User Image RetiredMD Posted - 6 days ago

$LUCD One month since T/A submission… How much longer?

User Image Carter113 Posted - 6 days ago

$LUCD $PAVM https://www.wvua23.com/tuscaloosa-firefighters-undergo-cancer-screening/

User Image supDawg Posted - 1 week ago

$LUCD I recommend selling your stocks and wait until the inevitable reverse split to buy back in.

User Image mmdetritus Posted - 1 week ago

@supDawg It's clear that they're getting a bit of near term revenue as they wait for Medicare coverage? I agree. $LUCD

User Image supDawg Posted - 1 week ago

$LUCD lol ... more firefighter PR's. it's clear folks.

User Image oaksapollo Posted - 1 week ago

$LUCD Lucid management - ENOUGH with the firefighters. We get it, you're knocking it out of the park in this niche market. It's time to expand beyond. Please no more firefighter PRs.

User Image TD_ Posted - 1 week ago

$LUCD $PAVM Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters https://ir.pavmed.com/2024-12-19-Lucid-Diagnostics-Partners-with-VITALExam-to-Enhance-Esophageal-Precancer-Detection-for-Firefighters

User Image oaksapollo Posted - 1 week ago

$LUCD In case anyone was wondering, here is where we're at with detecting esophageal cancer via the blood. Esoguard/Esocheck is going to be standard of care for a long, long time.

User Image RetiredMD Posted - 1 week ago

$LUCD A MolDX technical assessment response time can typically range from 3-4 weeks for tests requiring minimal additional documentation to up to 60 days for tests needing more extensive technical assessment documentation; this timeframe includes the review process by Palmetto GBA, the administrator of the MolDX program. Key points about MolDX technical assessments: What is MolDX? MolDX stands for "Molecular Diagnostic Services" and is a program by Palmetto GBA that assesses the clinical utility and coverage of new molecular diagnostic tests, determining if they meet Medicare's reasonable and necessary requirements. Technical Assessment Process: Labs need to submit a comprehensive dossier detailing their test's clinical data for review. Z-Code Identifier: Once a test is successfully assessed, it receives a unique Z-Code identifier which is used for billing purposes.

User Image oaksapollo Posted - 1 week ago

$LUCD Seems like MAYBE Ayrton is done, just based on volume last 2 days. Halfway through the day, we're only at 66K shares. Approaching 30 days post Moldx submission already. I can't say I have a solid handle on the timelines, but SOMETHING should happen within 60 days, even if it's just Moldx validating the submission. I think we could see this turn a corner YE as investors look for 2025 winners. It should be a transformative year for the company.

User Image supDawg Posted - 1 week ago

$PAVM $LUCD bulls name calling, sayin' nothing of substance, block me because (I'm right) ... Sorry, but the company issued more debt, which means they are still so far away from anything ... theyll keep selling their stake of $LUCD lower and lower until there's not much left. A sinking ship. The best thing they can do is sell off all of their assets including EsoGuard and retire for good.

User Image LPlates Posted - 1 week ago

@JRINPHX @Carter113 I had multiple positions in PAVM over probably nearly three years. Lishan fell in love with the PUMP and stopped trying to build a business. It was actually Veris that really got me going. An asset they bought for $188k was less than a year later worth 10's if not 100's of millions. It had no real IP as comprehensive IP exists from 18 years BEFORE Veris was founded. Then $LUCD and the clinics and how each was going to make BANK every month. It was just so misleading and false. Retail fell for it and I decided enough I would counter all Lishan & Dennis's deliberately misleading statements with facts. Institutional money having seen the LUCD roadshow decided Lishan was a bullshitter. Show me one other IPO where the parent had to buy nearly 10% of the offering to get it done. I have been blessed by generous people on Twitter who shared their expertise and I am trying to do the same here and collect some karma That's it. That's all.

Analyst Ratings
Ascendiant Capital Buy Sep 10, 24
Canaccord Genuity Buy Aug 13, 24
Needham Buy Aug 13, 24
Ascendiant Capital Buy Jun 6, 24
Cantor Fitzgerald Overweight May 15, 24
Needham Buy May 13, 24
Needham Buy Apr 12, 24
Cantor Fitzgerald Overweight Mar 27, 24
Needham Buy Mar 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lapidus Stanley Director Director Sep 25 Sell 1.45 29,947 43,423 101,592 09/27/23
Lapidus Stanley Director Director Sep 20 Sell 1.44 3,917 5,640 131,539 09/27/23
Lapidus Stanley Director Director Sep 20 Sell 1.7 33,864 57,569 135,456 09/22/22